This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2014 Feb 15;20(4):1053-4.

doi: 10.1158/1078-0432.CCR-13-2124.

GA201: a novel humanized and glycoengineered anti-EGFR antibody--letter

Helmout Modjtahedi¹, Suzanne Eccles

Affiliations

Affiliation

¹ Authors' Affiliations: Cancer Theme, School of Life Science, Kingston University London, Kingston; and Tumour Biology and Metastasis, Cancer Research UK Centre for Cancer Therapeutics McElwain Laboratories, Institute of Cancer Research, Sutton, Surrey, United Kingdom.

PMID: 24536074
DOI: 10.1158/1078-0432.CCR-13-2124

Comment

GA201: a novel humanized and glycoengineered anti-EGFR antibody--letter

Helmout Modjtahedi et al. Clin Cancer Res. 2014.

. 2014 Feb 15;20(4):1053-4.

doi: 10.1158/1078-0432.CCR-13-2124.

Authors

Helmout Modjtahedi¹, Suzanne Eccles

Affiliation

¹ Authors' Affiliations: Cancer Theme, School of Life Science, Kingston University London, Kingston; and Tumour Biology and Metastasis, Cancer Research UK Centre for Cancer Therapeutics McElwain Laboratories, Institute of Cancer Research, Sutton, Surrey, United Kingdom.

PMID: 24536074
DOI: 10.1158/1078-0432.CCR-13-2124

No abstract available

PubMed Disclaimer

Comment in

GA201: a novel humanized and glycoengineered anti-EGFR antibody--response.
Gerdes CA, Umaña P. Gerdes CA, et al. Clin Cancer Res. 2014 Feb 15;20(4):1055. doi: 10.1158/1078-0432.CCR-13-2699. Clin Cancer Res. 2014. PMID: 24536075 No abstract available.

Comment on

GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab.
Gerdes CA, Nicolini VG, Herter S, van Puijenbroek E, Lang S, Roemmele M, Moessner E, Freytag O, Friess T, Ries CH, Bossenmaier B, Mueller HJ, Umaña P. Gerdes CA, et al. Clin Cancer Res. 2013 Mar 1;19(5):1126-38. doi: 10.1158/1078-0432.CCR-12-0989. Epub 2012 Dec 3. Clin Cancer Res. 2013. PMID: 23209031

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

Grants and funding

11566/CRUK_/Cancer Research UK/United Kingdom

LinkOut - more resources

Full Text Sources
- Silverchair Information Systems
Other Literature Sources
- scite Smart Citations
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal